Affymetrix, Inc. AFFX today announced that it has signed a contract
with UK Biobank to genotype 500,000 DNA samples donated by UK residents as
part of a prospective epidemiological study of complex diseases that are of
great relevance to public health. Affymetrix' Axiom^® Genotyping Solution will
be used to generate billions of high-quality genotypes which will provide UK
Biobank and the research community with valuable insight to genetic factors
underlying human diseases for improved prevention, diagnosis, and treatment of
conditions such as heart disease, cancer, and diabetes.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in